Neuphoria Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

(NASDAQ:NEUP) BURLINGTON, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (Nasdaq: NEUP) (“Neuphoria” or the “Company”), a clinical-stage biotechnology company developing impactful treatments for neuropsychiatric disorders, today announced that Spyros Papapetropoulos, M.D., Ph.D., President and CEO, will be presenting at the H.C. Wainwright 27th Annual Global Investment Conference being held September 8-10, 2025 in New York, NY.